News

Intellia Therapeutics recently cancelled plans to include US-based sites in one of its mid-stage CRISPR trials due to the Food and Drug Administration’s request for additional data. This request was made to support the inclusion of female patients of childbearing …

The post Intellia Therapeutics Provides Reassurance Regarding Gene Editing Risks appeared first on isp.page.